## Top Drugs

	FDB Standard				HRA			% of		% of	Plan Net Paid	HRA Net Paid	Total Net Paid	Average	Ingredient Cost
	Therapeutic Metrics	Number of	Number of	Plan Net		Total Net	% of Total		% of HRA		per	per	per	Days	Paid per Day Of
Drug Name	Class		rescriptions	Paid	Paid		Prescriptions		Net Paid	Paid	Prescription	Prescription	Prescription	Supply	Therapy
HUMIRA PEN	ANTIARTHRITICS	12	79	\$321,507	\$0	\$321,507	0.1%	5.3%		5.3%	\$4,069.71	\$0.00	\$4,069.71	28.00	\$148.89
	Subtotal		79	\$321,507		\$321,507	0.1%	5.3%		5.3%	\$4,069.71	\$0.00	\$4,069.71	28.00	\$148.89
LANTUS SOLOSTAR	DIABETIC THERAPY	75	503	\$254,574	\$0	\$254,574	0.6%	4.2%	0.0%	4.2%	\$506.11	\$0.00	\$506.11	32.70	\$15.54
Latitob bollobilite	Subtotal		503	\$254,574	\$0	\$254,574	0.6%	4.2%	0.0%	4.2%	\$506.11	\$0.00	\$506.11	32.70	\$15.54
COPAXONE	MISCELLANEOUS	5	42	\$224,691	\$0	\$224,691	0.1%	3.7%	0.0%	3.7%	\$5,349.78	\$0.00	\$5,349.78	28.00	\$194.57
COPANONE	Subtotal		42	\$224,691	\$0	\$224,691	0.1%	3.7%	0.0%	3.7%	\$5,349.78	\$0.00	\$5,349.78	28.00	\$194.57
UTCHORN 2 DAY	DIABETIC THERAPY	32	253	\$189,152	\$0	\$189,152	0.3%	3.1%	0.0%	3.1%	\$747.64	\$0.00	\$747.64	31.34	\$24.08
VICTOZA 3-PAK	Subtotal		253	\$189,152	\$0	\$189,152	0.3%	3.1%	0.0%	3.1%	\$747.64	\$0.00	\$747.64	31.34	\$24.08
	ANTINEOPLASTICS	1	10	\$130,195	\$0	\$130,195	0.0%	2.1%	0.0%	2.1%	\$13,019.52	\$0.00	\$13,019.52	30.00	\$434.78
LENVIMA	Subtotal		10	\$130,195	\$0	\$130,195	0.0%	2.1%	0.0%	2.1%	\$13,019.52	\$0.00	\$13,019.52	30.00	\$434.78
	DIABETIC THERAPY	33	175	\$129,110	\$0	\$129,110	0.2%	2.1%	0.0%	2.1%	\$737.77	\$0.00	\$737.77	31.60	\$23.70
NOVOLOG FLEXPEN	Subtotal		175	\$129,110		\$129,110	0.2%	2.1%		2.1%	\$737.77	\$0.00	\$737.77	31.60	\$23.70
	ANTINEOPLASTICS	1	12	\$128,378		\$128,378	0.0%	2.1%		2.1%	\$10,698.17	\$0.00	\$10,698.17	30.00	\$366.49
SPRYCEL	Subtotal		12	\$128,378		\$128,378	0.0%	2.1%		2.1%	\$10,698.17	\$0.00	\$10,698.17	30.00	\$366.49
	OTHER HORMONES	3	16	\$124,292		\$124,292	0.0%	2.0%		2.0%	\$7,768.28	\$0.00	\$7,768.28	27.25	\$290.07
NUTROPIN AQ NUSPIN	Subtotal		16	\$124,292		\$124,292	0.0%	2.0%		2.0%	\$7,768.28	\$0.00	\$7,768.28	27.25	\$290.07
			30	\$116,512			0.0%	1.9%						26.67	
HUMIRA	ANTIARTHRITICS					\$116,512				1.9%	\$3,883.75	\$0.00	\$3,883.75		\$147.14
	Subtotal		30	\$116,512		\$116,512	0.0%	1.9%		1.9%	\$3,883.75	\$0.00	\$3,883.75	26.67	\$147.14
CRESTOR	LIPOTROPICS	83	494	\$114,380	· · ·	\$114,380	0.6%	1.9%	0.0%	1.9%	\$231.54	\$0.00	\$231.54	33.64	\$8.02
	Subtotal		494	\$114,380		\$114,380	0.6%	1.9%		1.9%	\$231.54	\$0.00	\$231.54	33.64	\$8.02
JANUVIA	DIABETIC THERAPY	34	269	\$109,167	\$0	\$109,167	0.3%	1.8%	0.0%	1.8%	\$405.82	\$0.00	\$405.82	32.52	\$12.61
	Subtotal		269	\$109,167	\$0	\$109,167	0.3%	1.8%		1.8%	\$405.82	\$0.00	\$405.82	32.52	\$12.61
HUMALOG	DIABETIC THERAPY	27	153	\$106,523	1.1	\$106,523	0.2%	1.8%	0.0%	1.8%	\$696.23	\$0.00	\$696.23	31.28	\$22.95
	Subtotal		153	\$106,523	\$0	\$106,523	0.2%	1.8%	0.0%	1.8%	\$696.23	\$0.00	\$696.23	31.28	\$22.95
LEVEMIR FLEXTOUCH	DIABETIC THERAPY	26	172	\$99,857	\$0	\$99,857	0.2%	1.6%	0.0%	1.6%	\$580.56	\$0.00	\$580.56	30.23	\$19.49
LEVEMIK FLEXIOOCH	Subtotal		172	\$99,857	\$0	\$99,857	0.2%	1.6%	0.0%	1.6%	\$580.56	\$0.00	\$580.56	30.23	\$19.49
SIMPONI	ANTIARTHRITICS	3	25	\$93,558	\$0	\$93,558	0.0%	1.5%	0.0%	1.5%	\$3,742.30	\$0.00	\$3,742.30	29.60	\$127.78
SIMPONI	Subtotal		25	\$93,558	\$0	\$93,558	0.0%	1.5%	0.0%	1.5%	\$3,742.30	\$0.00	\$3,742.30	29.60	\$127.78
	ANTIARTHRITICS	4	21	\$86,641	\$0	\$86,641	0.0%	1.4%	0.0%	1.4%	\$4,125.77	\$0.00	\$4,125.77	28.00	\$154.62
ENBREL	Subtotal		21	\$86,641	\$0	\$86,641	0.0%	1.4%	0.0%	1.4%	\$4,125.77	\$0.00	\$4,125.77	28.00	\$154.62
	BRONCHIAL DILATORS	63	240	\$83,464	\$0	\$83,464	0.3%	1.4%	0.0%	1.4%	\$347.77	\$0.00	\$347.77	36.25	\$11.77
ADVAIR DISKUS	Subtotal		240	\$83,464	\$0	\$83,464	0.3%	1.4%	0.0%	1.4%	\$347.77	\$0.00	\$347.77	36.25	\$11.77
	DIABETIC THERAPY	31	201	\$82,078	\$0	\$82,078	0.3%	1.4%	0.0%	1.4%	\$408.35	\$0.00	\$408.35	32.28	\$12.94
INVOKANA	Subtotal		201	\$82,078		\$82,078	0.3%	1.4%		1.4%	\$408.35	\$0.00	\$408.35	32.28	\$12.94
	DIAGNOSTICS	144	580	\$70,326		\$70,326	0.7%	1.2%		1.2%	\$121.25	\$0.00	\$121.25	31.98	\$3.86
ONETOUCH ULTRA TEST STRIPS	Subtotal		580	\$70,326		\$70,326	0.7%	1.2%		1.2%	\$121.25	\$0.00	\$121.25	31.98	\$3.86
	AMPHETAMINE PREPARATIONS	50	331	\$69,424		\$69,424	0.4%	1.1%		1.1%	\$209.74	\$0.00	\$209.74	29.98	\$7.99
ADDERALL XR	Subtotal		331	\$69,424		\$69,424	0.4%	1.1%		1.1%	\$209.74	\$0.00	\$209.74	29.98	\$7.99
	ATARACTICS-TRANQUILIZERS	22	145	\$69,098		\$69,098	0.2%	1.1%		1.1%	\$476.54	\$0.00	\$476.54	29.30	\$17.20
ARIPIPRAZOLE	Subtotal		145	\$69,098			0.2%	1.1%		1.1%	\$476.54		\$476.54	29.30	\$17.20
	DIABETIC THERAPY	13	145	\$63,414		\$69,098 \$63,414	0.2%	1.0%	0.0%	1.0%	\$634.14	\$0.00 \$0.00	\$634.14	30.20	\$17.20
TRULICITY					· · ·										
	Subtotal		100	\$63,414		\$63,414	0.1%	1.0%		1.0%	\$634.14	\$0.00	\$634.14	30.20	\$21.73
DARAPRIM	ANTIMALARIALS	1	7	\$62,526		\$62,526	0.0%	1.0%		1.0%	\$8,932.29	\$0.00	\$8,932.29	28.00	\$320.42
	Subtotal		7	\$62,526		\$62,526	0.0%	1.0%		1.0%	\$8,932.29	\$0.00	\$8,932.29	28.00	\$320.42
XARELTO	ANTICOAGULANTS	29	175	\$61,614		\$61,614	0.2%	1.0%		1.0%	\$352.08	\$0.00	\$352.08	33.08	\$12.02
v	Subtotal		175	\$61,614		\$61,614	0.2%	1.0%		1.0%	\$352.08	\$0.00	\$352.08	33.08	\$12.02
CIMZIA	MISCELLANEOUS	2	18	\$61,466		\$61,466	0.0%	1.0%	0.0%	1.0%	\$3,414.79	\$0.00	\$3,414.79	28.00	\$123.39
	Subtotal		18	\$61,466	\$0	\$61,466	0.0%	1.0%	0.0%	1.0%	\$3,414.79	\$0.00	\$3,414.79	28.00	\$123.39
HARVONI	ANTIVIRALS	2	2	\$60,875	\$0	\$60,875	0.0%	1.0%	0.0%	1.0%	\$30,437.25	\$0.00	\$30,437.25	28.00	\$1,088.44
Indice ON L	Subtotal		2	\$60,875	\$0	\$60,875	0.0%	1.0%	0.0%	1.0%	\$30,437.25	\$0.00	\$30,437.25	28.00	\$1,088.44
Subtotal			4,053	\$2,912,821	\$0 \$	\$2,912,821	5.2%	48.0%	0.0%	48.0%	\$718.68	\$0.00	\$718.68	31.91	\$23.30

## All Other Drugs

				HRA			% of		% of	Plan Net Paid	HRA Net Paid	Total Net Paid	Average	Ingredient Cost
Metrics	Number of	Number of	Plan Net	Net	Total Net	% of Total	Plan Net	% of HRA	Total Net	per	per	per	Days	Paid per Day Of
	Claimante	Prescriptions	Daid	Daid	Daid /	Prescriptions	Paid	Mat Daid	Daid	Descarintion	Dreagnintion	Prescription	Supply	Therapy
	Crarmanco	FIESCIIPCIONS	Faiu	Faiu	Faid	FIGRCLIPCIONS	Faiu	Net Para	Paiu	Prescription	Prescription	Prescription	Suppry	Inerapy

This document contains UnitedHealthcare's confidential and/or proprietary business information (PBI). PBI may only be used by the recipient person/entity to which it is addressed. Recipient is liable for using and protect UnitedHealthcare's PBI from further disclosure or misuse, consistent with recipient's contractual obligations under any applicable administrative services agreement, group policy contract, non-disclosure agreement or othe contract or law, including but not limited to the U.S. Freedom of Information Act and state freedom of information law exemptions for "trade secrets". The document may also contain protected health information (PHI) and m according to applicable state and federal law, including, but not limited to HIPAA. Recipients who misuse information may be subject to both civil and criminal penalties.

				HRA			% of				HRA Net Paid	Total Net Paid	Average	Ingredient Cost
Metrics	Number of	Number of	Plan Net	Net	Total Net	% of Total	Plan Net	% of HRA	Total Net	per	per	per	Days	Paid per Day Of
	Claimants	Prescriptions	Paid	Paid	Paid	Prescriptions	Paid	Net Paid	Paid	Prescription	Prescription	Prescription	Supply	Therapy
	4,176	77,409	\$6,066,729	\$0	\$6,066,729	100.0%	100.0%	0.0%	100.0%	\$78.37	\$0.00	\$78.37	29.16	\$3.13

This document contains UnitedHealthcare's confidential and/or proprietary business information (PBI). PBI may only be used by the recipient person/entity to which it is addressed. Recipient is liable for using and protect UnitedHealthcare's PBI from further disclosure or misuse, consistent with recipient's contractual obligations under any applicable administrative services agreement, group policy contract, non-disclosure agreement or othe contract or law, including but not limited to the U.S. Freedom of Information (PHI) and m according to applicable state and federal law, including, but not limited to HIPAA. Recipients who misuse information may be subject to both civil and criminal penalties.